Aurobindo Pharma Wins Company of the Year and Acquisition of the Year Awards at the Global Generics & Biosimilars Awards 2019
HYDERABAD, India, Nov. 21, 2019 /PRNewswire/ -- Aurobindo Pharma Limited (BSE: 524804 and NSE: AUROPHARMA) ("Aurobindo"), a world-leading marketer and manufacturer of generic pharmaceuticals and active pharmaceutical ingredients, is pleased to announce that it won two prestigious awards at the 6th Global Generics & Biosimilars Awards 2019 ceremony held on 5th November 2019 in Frankfurt, Germany: Company of the Year and Acquisition of the Year.
Aurobindo has been recognised as the Company of the Year for its outstanding development, innovation and success over the past year. The Acquisition of the Year award was given to Aurobindo following its acquisition of Sandoz Inc., USA's dermatology and oral solids businesses in the United States.
"We are delighted and honoured to be recognised once again at the Generics & Biosimilars Awards 2019, winning one of the most coveted prizes this year – the Company of the Year Award. This award is an acknowledgement of the incredible progress we have made towards becoming a world-leading generic pharmaceutical company and recognition of our commitment to delivering and providing access to safe, high-quality and affordable generic drugs worldwide. Together with the Acquisition of the Year award, these awards are an endorsement of our strategy to strengthen and grow our global business and expand and enhance our product portfolio offerings. I would like to thank the many teams for all their hard work and congratulate them for the success achieved to date," said V. Muralidharan, President of European operations at Aurobindo.
The Global Generics & Biosimilars Awards presented by Generics Bulletin in association with IQVIA, a leading global provider of information and innovative technology solutions for healthcare clients, are amongst the most coveted recognitions in the pharmaceutical industry. The Awards honour the year's most outstanding achievements across the generics, biosimilars and value-added medicines industries, recognising and rewarding efforts to make more affordable medicines available to more people everywhere.
Aurobindo Pharma Limited (www.aurobindo.com) (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP:IN), is a world-leading marketer and manufacturer of generic pharmaceuticals and active pharmaceutical ingredients. The company's robust product portfolio is spread over major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Systemic Gastroenterologicals, Anti-Allergies, Anti-Diabetics and other therapeutic areas. The US and Europe are Aurobindo's two most important markets accounting for over 70% of the company's $2.8 billion sales. The company's new product development activities are driven by an outstanding R&D organization. The company's manufacturing facilities are approved by the world's leading regulatory agencies including US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. Aurobindo is headquartered in Hyderabad, India.
For further information, please contact:
Phone: +91-040-66725401 / 66725000
Citigate Dewe Rogerson
Caroline Merrell, Sylvie Berrebi, David Dible, Nick Reading, Michael Russell
This press release contains statements that may constitute "forward looking statements" including and without limitation, statements relating to product characteristics and uses, sales potential and target dates for product launch, implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward-looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other factors could cause actual developments and results to differ materially from our expectations. The company undertakes no obligation to publicly revise any forward-looking statements to reflect future events or circumstances and will not be held liable for any use of this information.